PDCD1 and gastric cancer: Immune checkpoint inhibitors (ICIs), including antibodies against programmed cell death protein-1 (PD-1) or its ligand (PD-L1), have been rapidly developed over the past few years and are now established treatments for chemotherapy-refractory gastric cancers (cancers that progress after two or more lines of chemotherapy) (6, 7).